ptc-209 and palbociclib

ptc-209 has been researched along with palbociclib* in 1 studies

Other Studies

1 other study(ies) available for ptc-209 and palbociclib

Article	Year
Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo. Scientific reports, 2019, 09-23, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Heterocyclic Compounds, 2-Ring; Humans; Mitogen-Activated Protein Kinase 7; Piperazines; Protein Kinase Inhibitors; Pyridines; Thiazoles	2019

Article

Year

Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo.

Scientific reports, 2019, 09-23, Volume: 9, Issue:1

Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Heterocyclic Compounds, 2-Ring; Humans; Mitogen-Activated Protein Kinase 7; Piperazines; Protein Kinase Inhibitors; Pyridines; Thiazoles

2019